Ra Capital Management, L.p. bought $4.8M of BCAX
director, owner at Bicara Therapeutics Inc.. 300,000 shares at an average of $16.00, traded Feb 26, 2026, filed Mar 2, 2026.
Score components
- +15RoleDirector
- +25Trade size$4.8M at market
- +3Relative to holdingsHoldings up 7%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -38% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000231, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +300,000 | $16.00 | $4.8M | 4,603,418 | Mar 2, 2026 |
| Feb 26, 2026 | POpen-market purchase Pre-Funded Warrant (Right to Buy)derivativeindirect: See Footnotes | +2,200,000 | $16.00 | $35M | 2,200,000 | Mar 2, 2026 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 5Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $104k 5,500 shares | -9% | |
| 13Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $170k 9,200 shares | -6% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $282k 15,000 shares | -4% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $246k 12,500 shares | -6% | |
| 26Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $705k 36,766 shares | -10% | |
| 16Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $154k 8,234 shares | -2% | |
| 19Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $306k 16,500 shares | -30% | |
| 21Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $301k 16,518 shares | -10% | |
| 14Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $316k 17,392 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.